Zituvimet Tablet, Film Coated
Product Images NDC 70771-1859

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Zituvimet (NDC 70771-1859). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Zydus Lifesciences Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (F9c7f395 5f9f 4682 B3f4 Ed27e5ec62d8 01)

Chemical structure of the active ingredient Sitagliptin in the drug product ZITUVIMET. The diagram shows the molecular arrangement including fluorine atoms and a trifluoromethyl group attached to a nitrogen-containing ring system.*

FDA Label Image

Structure (F9c7f395 5f9f 4682 B3f4 Ed27e5ec62d8 02)

Chemical structure of Sitagliptin Hydrochloride, showing its molecular arrangement with the hydrochloride (HCl) component.*

FDA Label Image

Graph (F9c7f395 5f9f 4682 B3f4 Ed27e5ec62d8 03)

A line graph depicting the least squares mean change from baseline over 24 weeks for various treatment groups including placebo, Metformin 1000 mg twice daily, Sitagliptin 100 mg once daily, Sitagliptin 50 mg once daily plus Metformin 500 mg twice daily, and Sitagliptin 50 mg once daily plus Metformin 1000 mg twice daily. The x-axis shows time in weeks, and the y-axis shows change from baseline.*

FDA Label Image

Graph (F9c7f395 5f9f 4682 B3f4 Ed27e5ec62d8 04)

A line graph comparing the least squares mean change from baseline over 52 weeks for Sitagliptin 100 mg and Glipizide. The x-axis represents weeks (0 to 52), and the y-axis represents LS mean change from baseline, ranging from 0.0 to -1.5. Both treatments show a similar pattern of decrease and slight increase over time.*

FDA Label Image

Label (F9c7f395 5f9f 4682 B3f4 Ed27e5ec62d8 05)

Label for ZITUVIMET 50 mg/500 mg film-coated tablets containing sitagliptin and metformin hydrochloride. The package includes 60 tablets and is labeled for prescription use only. Manufactured by Zydus Lifesciences Limited, the label features dosage information and storage instructions, including use within 3 months after opening and child-resistant packaging.*

FDA Label Image

Label (F9c7f395 5f9f 4682 B3f4 Ed27e5ec62d8 06)

The label for ZITUVIMET tablets contains sitagliptin 50 mg and metformin hydrochloride 1,000 mg per film-coated tablet. It shows the NDC 70771-1860-6 and states it is manufactured by Zydus Lifesciences Limited. The label includes directions to dispense the medication guide to patients and store the medication in the original container. It specifies 60 tablets per bottle and highlights child-resistant packaging and storage temperature guidelines.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.